Index

A synthetic fifteen-amino-acid peptide derived from a protein in human gastric juice, studied since the early 1990s almost entirely in rodents.

A modified analogue of growth-hormone-releasing hormone (GHRH 1-29). The 'no DAC' form lacks the drug-affinity complex that extends the half-life of the DAC version.

A copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, used for decades in topical cosmetic formulations.

A pentapeptide growth-hormone secretagogue that acts on the ghrelin receptor, developed in the 1990s and studied for post-operative ileus before development stopped.

A sixteen-amino-acid peptide encoded in the mitochondrial genome, described in 2015 as a regulator of metabolic homeostasis.

An investigational once-weekly agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly.

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and weight management, with an oral peptide form for weight management approved in late 2025.

A synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair.

A stabilised GHRH analogue approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.